| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/BF02088068 |
| P698 | PubMed publication ID | 8026273 |
| P2093 | author name string | A Durand | |
| J C Montet | |||
| E Mesdjian | |||
| M Guitaoui | |||
| P Bertault-Peres | |||
| P E Queneau | |||
| P2860 | cites work | A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 |
| Effects of Bile Salt Infusion on Chlorpromazine-lnduced Cholestasis in the Isolated Perfused Rat Liver | Q28324353 | ||
| Excretion of cyclosporine and its metabolites in human bile. | Q33993557 | ||
| Cyclosporine | Q38733507 | ||
| Cyclosporine: toxicity, metabolism, and drug interactions--implications from animal studies | Q39826189 | ||
| Re-evaluation of the 3 alpha-hydroxysteroid dehydrogenase assay for total bile acids in bile | Q40344262 | ||
| Cholesterol gallstone dissolution in bile. Dissolution kinetics of crystalline cholesterol monohydrate by conjugated chenodeoxycholate-lecithin and conjugated ursodeoxycholate-lecithin mixtures: dissimilar phase equilibria and dissolution mechanisms | Q41609128 | ||
| Effects of ursodeoxycholic acid on liver function in patients with cystic fibrosis and chronic cholestasis | Q43551362 | ||
| Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular necrosis caused by more hydrophobic bile salts. In vivo studies in the rat. | Q44951192 | ||
| Effects of bile salt supplementation on biliary secretion in estrogen-treated rats | Q45147811 | ||
| Tauroursodeoxycholate and tauro-beta-muricholate exert cytoprotection by reducing intrahepatocyte taurochenodeoxycholate content. | Q50784679 | ||
| Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes. | Q50878460 | ||
| The hydrophobic-hydrophilic balance of bile salts. Inverse correlation between reverse-phase high performance liquid chromatographic mobilities and micellar cholesterol-solubilizing capacities. | Q52730069 | ||
| Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. | Q54072767 | ||
| Cholestatic effect of cyclosporine in the rat. An inhibition of bile acid secretion | Q67943501 | ||
| Adjuvant treatment with ursodeoxycholic acid reduces acute rejection after liver transplantation | Q68062883 | ||
| Effects of ursodeoxycholic acid and taurine on serum liver enzymes and bile acids in chronic hepatitis | Q68084449 | ||
| Effects of ursodeoxycholic acid in patients with intrahepatic cholestasis of pregnancy | Q68134805 | ||
| Hepatocellular uptake of cyclosporin A by simple diffusion | Q68255216 | ||
| Inhibition of Taurocholate and Ouabain Transport in Isolated Rat Hepatocytes by Cyclosporin A | Q68450005 | ||
| [Improved method of orthophosphate determination] | Q68647230 | ||
| Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid | Q68925952 | ||
| Cyclosporin A-induced cholestasis. The mechanism in a rat model | Q69058160 | ||
| beta-Muricholic acid; potentiometric and cholesterol-dissolving properties | Q69780551 | ||
| Cyclosporin and rifampicin in renal transplantation | Q69860974 | ||
| Tissue distribution, disposition, and metabolism of cyclosporine in rats | Q69902754 | ||
| Ursodeoxycholic acid for primary biliary cirrhosis | Q69903541 | ||
| Effect of rifampicin on cyclosporin A blood levels in a renal transplant recipient | Q69910265 | ||
| Cyclosporin A and a diaziridine derivative inhibit the hepatocellular uptake of cholate, phalloidin and rifampicin | Q69993918 | ||
| Tauroursodeoxycholate prevents taurocholate induced cholestasis | Q70316364 | ||
| Thermodynamic and molecular basis for dissimilar cholesterol-solubilizing capacities by micellar solutions of bile salts: cases of sodium chenodeoxycholate and sodium ursodeoxycholate and their glycine and taurine conjugates | Q70864798 | ||
| Nature of the toxicity of cyclosporin A in the rat | Q71061592 | ||
| Use of a simple enzymatic assay for cholesterol analysis in human bile | Q71187652 | ||
| P433 | issue | 7 | |
| P304 | page(s) | 1581-1585 | |
| P577 | publication date | 1994-07-01 | |
| P1433 | published in | Digestive Diseases and Sciences | Q15716711 |
| P1476 | title | Improvement of cyclosporin A-induced cholestasis by tauroursodeoxycholate in a long-term study in the rat | |
| P478 | volume | 39 |
| Q64898654 | CYP2E1 and CYP3A1/2 gene expression is not associated with the ursodeoxycholate effect on ethanol-induced lipoperoxidation. |
| Q28359638 | Cyclosporin A reduces canalicular membrane fluidity and regulates transporter function in rats |
| Q43641326 | Effect of sodium tauroursodeoxycholate on phalloidin-induced cholestasis in rats |
| Q44405390 | Effects of ursodeoxycholic acid (ursodiol) treatment on chronic viral hepatitis in heart transplant patients: results of a prospective, double-blind, placebo-randomized study |
| Q44781575 | Everolimus/cyclosporine interactions on bile flow and biliary excretion of bile salts and cholesterol in rats |
| Q42552188 | Flutamide-induced toxic hepatitis. Potential utility of ursodeoxycholic acid administration in toxic hepatitis |
| Q43006246 | Hepatoprotection with tauroursodeoxycholate and beta muricholate against taurolithocholate induced cholestasis: involvement of signal transduction pathways |
| Q34210636 | Intrahepatic cholestasis following liver transplantation |
| Q40995439 | Management of biliary tract stones in heart transplant patients |
| Q77741767 | Ursodeoxycholate protects against ethanol-induced liver mitochondrial injury |
Search more.